이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

HTG Molecular Diagnostics 관리

관리 기준 확인 2/4

HTG Molecular Diagnostics' CEO는 John Lubniewski, Apr2018 에 임명되었습니다 의 임기는 6.17 년입니다. 총 연간 보상은 $ 913.89K, 58.9% 로 구성됩니다. 58.9% 급여 및 41.1% 보너스(회사 주식 및 옵션 포함). 는 $ 2.94 가치에 해당하는 회사 주식의 0.053% 직접 소유합니다. 2.94. 경영진과 이사회의 평균 재임 기간은 각각 8.2 년과 5.2 년입니다.

주요 정보

John Lubniewski

최고 경영자

US$913.9k

총 보상

CEO 급여 비율	58.9%
CEO 임기	6.2yrs
CEO 소유권	0.05%
경영진 평균 재임 기간	8.2yrs
이사회 평균 재임 기간	5.2yrs

최근 관리 업데이트

Recent updates

These Analysts Think HTG Molecular Diagnostics, Inc.'s (NASDAQ:HTGM) Sales Are Under Threat

Mar 26

What Type Of Returns Would HTG Molecular Diagnostics'(NASDAQ:HTGM) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Jan 20

HTG shares surge after upbeat 2020 revenue forecast

Jan 05

HTG Molecular Diagnostics announced 1:15 reverse stock split

Nov 23

HTG Molecular Diagnostics (HTGM) Investor Presentation - Slideshow

Nov 18

CEO 보상 분석

John Lubniewski 의 보수는 HTG Molecular Diagnostics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2023	n/a	n/a	-US$20m
Dec 31 2022	US$914k	US$538k	-US$22m
Sep 30 2022	n/a	n/a	-US$22m
Jun 30 2022	n/a	n/a	-US$22m
Mar 31 2022	n/a	n/a	-US$19m
Dec 31 2021	US$737k	US$460k	-US$17m
Sep 30 2021	n/a	n/a	-US$16m
Jun 30 2021	n/a	n/a	-US$17m
Mar 31 2021	n/a	n/a	-US$20m
Dec 31 2020	US$1m	US$416k	-US$21m
Sep 30 2020	n/a	n/a	-US$21m
Jun 30 2020	n/a	n/a	-US$20m
Mar 31 2020	n/a	n/a	-US$19m
Dec 31 2019	US$1m	US$384k	-US$19m
Sep 30 2019	n/a	n/a	-US$17m
Jun 30 2019	n/a	n/a	-US$17m
Mar 31 2019	n/a	n/a	-US$16m
Dec 31 2018	US$1m	US$327k	-US$16m
Sep 30 2018	n/a	n/a	-US$16m
Jun 30 2018	n/a	n/a	-US$17m
Mar 31 2018	n/a	n/a	-US$19m
Dec 31 2017	US$691k	US$307k	-US$19m

보상 대 시장: John 의 총 보상 ($USD 913.89K )은 US 시장( $USD 683.56K ).

보상과 수익: 회사가 수익성이 없는 동안 John 의 보상이 증가했습니다.

CEO

John Lubniewski (60 yo)

6.2yrs

테뉴어

US$913,891

보상

Mr. John L. Lubniewski serves as President of HTG Molecular Diagnostics, Inc. since April 16, 2018 and also serves as its Chief Executive Officer since April 2019. Mr. Lubniewski served as Chief Operating...

리더십 팀

이름	위치	테뉴어	보상	소유권
John Lubniewski	President	6.2yrs	US$913.89k	0.053% $ 1.8
Shaun McMeans	Senior VP	12.3yrs	US$580.32k	0.040% $ 1.3
Laura Godlewski	Senior Vice President of Finance & Administration	2.4yrs	데이터 없음	0.018% $ 0.6
Debra Gordon	Senior VP & Chief Legal Counsel	13yrs	US$296.70k	데이터 없음
Patrick Roche	Senior Vice President of Research & Development	10.2yrs	US$507.38k	데이터 없음
Stephen Barat	Senior Vice President of Therapeutics	2.7yrs	데이터 없음	0.019% $ 0.6
Christina Carruthers	Vice President of Target Strategy & Early Development	no data	데이터 없음	데이터 없음
Debrah Thompson	Vice President of Scientific Innovation	no data	데이터 없음	데이터 없음

8.2yrs

평균 재임 기간

61yo

평균 연령

경험이 풍부한 관리: HTGM.Q 의 관리팀은 노련하고 경험 (평균 재직 기간 8.2 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
John Lubniewski	President	5.2yrs	US$913.89k	0.053% $ 1.8
Michelle Griffin	Independent Director	5.8yrs	US$54.75k	0.00059% $ 0.02
Lee McCracken	Independent Director	8.7yrs	US$49.41k	0.0012% $ 0.04
Ann Hanham	Independent Chairman of the Board	7.8yrs	US$80.05k	0.0018% $ 0.06
Thomas Dubensky	Independent Director	1.8yrs	US$11.00k	데이터 없음
Christopher Kiritsy	Non-Employee Independent Director	2.4yrs	US$53.83k	0% $ 0
Davide Ruggero	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Frank Slack	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Robert Spitale	Member of Therapeutics Scientific Advisory Board	2.3yrs	데이터 없음	데이터 없음
Amir Horowitz	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Mateusz Koptyra	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Kendall Van Keuren-Jensen	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음

5.2yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 이사회: HTGM.Q 의 이사회는 경험(평균 재직 기간 5.2 년)으로 간주됩니다.

HTG Molecular Diagnostics 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Htg Molecular Diagnostics, Inc. Announces Termination of Employment of Byron T. Lawson as Senior Vice President and Chief Commercial Officer

HTG Molecular Diagnostics, Inc. Announces Board Changes

HTG Molecular Diagnostics, Inc., Annual General Meeting, Aug 17, 2022

HTG Molecular Diagnostics, Inc. Appoints Dr. Robert Spitale to Therapeutics Scientific Advisory Board

HTG Molecular Diagnostics, Inc. Appoints Christopher P. Kiritsy to Serve as Class I Director, Member of Audit Committee

HTG Molecular Diagnostics, Inc. Announces Resignation of Timothy B. Johnson as Executive Chairman and a Member of the Board of Directors

Recent updates

Nasdaq to Delist the Common Stock of HTG Molecular Diagnostics

HTG Molecular Diagnostics, Inc.(OTCPK:HTGM.Q) dropped from NASDAQ Composite Index

HTG Molecular Diagnostics, Inc.(NasdaqCM:HTGM) dropped from S&P TMI Index

Htg Molecular Diagnostics, Inc. Announces Termination of Employment of Byron T. Lawson as Senior Vice President and Chief Commercial Officer

HTG Molecular Diagnostics, Inc. Filed for Bankruptcy

HTG Molecular Diagnostics Receives Non-Compliance Notice From Nasdaq

HTG Molecular Diagnostics, Inc. to Highlight the Advantages of its Drug Discovery Engine at the 2023 Biotechnology Innovation Organization

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings: EPS misses analyst expectations

Consensus forecasts updated

HTG Molecular Diagnostics, Inc. Provides a Year-End Update on its Drug Discovery Business and Attends LifeSci Partners 2023 Corporate Access Event

HTG Molecular Diagnostics, Inc. Provides Revenue Guidance for Full Year 2022

HTG Molecular Diagnostics, Inc. has completed a Follow-on Equity Offering.

HTG Molecular Diagnostics, Inc. Receives Non-Compliance Notice From Nasdaq

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

HTG Molecular Diagnostics, Inc. announced that it has received $0.0001 million in funding

HTG Molecular Diagnostics Receives Non-Compliance Letter from Nasdaq

Consensus forecasts updated

HTG Molecular Diagnostics, Inc. Announces Board Changes

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

HTG Molecular Q2 GAAP loss per share widens, revenue down

HTG Molecular Diagnostics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Price target decreased to US$3.25

HTG Molecular Diagnostics amends senior loan facility

HTG Molecular Diagnostics, Inc., Annual General Meeting, Aug 17, 2022

HTG Molecular Diagnostics, Inc. Releases Second Whitepaper for Its Transcriptome-Informed Approach to Drug Discovery

HTG Molecular Diagnostics Receives Non-Compliance Letter from Nasdaq

Consensus forecasts updated

HTG Molecular Diagnostics, Inc. Provides Revenue Guidance for the Full Year 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

HTG Molecular Diagnostics, Inc. to Report Q1, 2022 Results on May 12, 2022

Price target decreased to US$9.50

HTG Molecular Diagnostics, Inc. Expands Features of Proprietary HTG EdgeSeq Technology

Consensus revenue estimates fall by 16%

Full year 2021 earnings: EPS exceeds analyst expectations

HTG Molecular Diagnostics, Inc. Appoints Dr. Robert Spitale to Therapeutics Scientific Advisory Board

HTG Molecular Diagnostics, Inc. Appoints Christopher P. Kiritsy to Serve as Class I Director, Member of Audit Committee

HTG Molecular Diagnostics, Inc. Provides Revenue Guidance for the Full Year 2021

HTG Molecular Diagnostics, Inc. Completes HTP Product Next-Phase Development Milestone

Is HTG Molecular Diagnostics (NASDAQ:HTGM) Using Debt In A Risky Way?

Third quarter 2021 earnings released: US$0.60 loss per share (vs US$1.12 loss in 3Q 2020)

Is HTG Molecular Diagnostics (NASDAQ:HTGM) Weighed On By Its Debt Load?

Consensus forecasts updated

Second quarter 2021 earnings released: US$0.39 loss per share (vs US$1.30 loss in 2Q 2020)

HTG Molecular Diagnostics, Inc. Announces Commercial Launch and Immediate Availability of its HTG Transcriptome Panel

HTG Molecular Diagnostics, Inc. Announces Completion of Product Design Lock for the HTG Transcriptome Panel

HTG Molecular completes product design lock for planned transcriptome panel

First quarter 2021 earnings released: US$0.64 loss per share (vs US$1.27 loss in 1Q 2020)

Price target decreased to US$9.75

HTG Molecular Diagnostics, Inc. Reports Preliminary Financial Results for the First Quarter Ended March 31, 2021 and Full Year 2021

Full year 2020 earnings released: US$4.51 loss per share (vs US$7.60 loss in FY 2019)

Consensus forecasts updated

Price target decreased to US$11.75

These Analysts Think HTG Molecular Diagnostics, Inc.'s (NASDAQ:HTGM) Sales Are Under Threat

HTG Molecular Diagnostics, Inc. to Report Fiscal Year 2020 Results on Mar 25, 2021

HTG Concludes Feasibility Testing & Releases Second White Paper for its Planned Whole Transcriptome Panel Using HTG EdgeSeq Technology

New 90-day high: US$7.83

New 90-day high: US$7.27

HTG Molecular Diagnostics, Inc. Announces Resignation of Timothy B. Johnson as Executive Chairman and a Member of the Board of Directors

What Type Of Returns Would HTG Molecular Diagnostics'(NASDAQ:HTGM) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Price target lowered to US$9.25

New 90-day high: US$6.10

HTG shares surge after upbeat 2020 revenue forecast

New 90-day high: US$5.61

Analysts update estimates

HTG Molecular Diagnostics announced 1:15 reverse stock split

HTG Molecular Diagnostics (HTGM) Investor Presentation - Slideshow